Show simple item record

dc.contributor.authorTurner, N
dc.contributor.authorOliveira, M
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorSablin, M
dc.contributor.authorPerez-Fidalgo, J
dc.contributor.authorHerebien, S
dc.contributor.authorGarcia-Murillas, I
dc.contributor.authorJohnson, S
dc.contributor.authorFoxley, A
dc.contributor.authorMahmood, A
dc.contributor.authorLindemann, J
dc.date.accessioned2016-04-25T11:26:53Zen
dc.date.available2016-04-25T11:26:53Zen
dc.date.issued2015-08-02en
dc.identifier.citation“BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s 2015, 75 (15 Supplement):CT331 Cancer Resen
dc.identifier.issn0008-5472en
dc.identifier.issn1538-7445en
dc.identifier.doi10.1158/1538-7445.AM2015-CT331en
dc.identifier.urihttp://hdl.handle.net/10541/606937en
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2015-CT331en
dc.rightsArchived with thanks to Cancer Researchen
dc.title“BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a sen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Royal Marsden Hospital, Londonen
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record